ADGM Stock Overview
A developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Adagio Medical Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.86 |
| 52 Week High | US$11.57 |
| 52 Week Low | US$2.80 |
| Beta | -0.034 |
| 11 Month Change | -44.47% |
| 3 Month Change | -75.07% |
| 1 Year Change | -73.57% |
| 33 Year Change | -71.54% |
| 5 Year Change | n/a |
| Change since IPO | -74.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADGM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -25.7% | -0.6% | 0.9% |
| 1Y | -73.6% | 20.8% | 32.3% |
Return vs Industry: ADGM underperformed the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: ADGM underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| ADGM volatility | |
|---|---|
| ADGM Average Weekly Movement | 20.4% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ADGM's share price has been volatile over the past 3 months.
Volatility Over Time: ADGM's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 87 | Olav Bergheim | adagiomedical.com |
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories.
Adagio Medical Holdings, Inc. Fundamentals Summary
| ADGM fundamental statistics | |
|---|---|
| Market cap | US$38.29m |
| Earnings (TTM) | -US$34.80m |
| Revenue (TTM) | US$399.00k |
96.0x
P/S Ratio-1.1x
P/E RatioIs ADGM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADGM income statement (TTM) | |
|---|---|
| Revenue | US$399.00k |
| Cost of Revenue | US$1.81m |
| Gross Profit | -US$1.41m |
| Other Expenses | US$33.39m |
| Earnings | -US$34.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.60 |
| Gross Margin | -353.88% |
| Net Profit Margin | -8,721.80% |
| Debt/Equity Ratio | -91.6% |
How did ADGM perform over the long term?
See historical performance and comparison